

IMMUNIZATIONS, VACCINATIONS, AND OTHER MISCELLANEOUS TREATMENTS	DEFER FOR:
Allergy Desensitization	Accept immediately
Anthrax	Accept immediately if feeling well and healthy
Botulinum Toxin ('Botox')	Defer for 24 hours after treatment
BCG	2 weeks
Chicken Pox (Varivax)	4 weeks
Chicken Pox (VZIG) Immune Globulin	12 months
Cholera	Accept immediately if feeling well and healthy
COVID-19	<ul style="list-style-type: none"> • Accept immediately if feeling well and healthy after receiving a Non-Replicating, Inactivated, Viral Vector (such as Johnson & Johnson), mRNA (such as Pfizer/BioNTech, Comirnaty or Moderna) or subunit protein (such as Novavax) vaccine that has been approved in the USA • 2 weeks if feeling well and healthy after receiving a vaccine that has not been approved and is in clinical trials in USA, Europe, Canada, or Australia (such as AstraZeneca (Covishield)/Oxford, CureVac, and Sanofi/GSK) • 2 weeks If the donor does not remember the name of the vaccine and received it in USA, Europe, Canada, or Australia • 1 year if feeling well and healthy after receiving a vaccine in use or in clinical trials in countries other than USA, Europe, Canada, or Australia (such as Cansino, Bharat, Gamaleya, Sinopharm (Beijing), Sinopharm (Wuhan), Sinovac Biotech, Sputnik V and Vector Institute) • 1 year if the donor does not remember the name of the vaccine and received it in a country other than USA, Europe, Canada, or Australia • Refer to NY-JA-0521 "<i>COVID-19 Vaccine List with Deferral Intervals</i>" for COVID-19 vaccinations not listed
Diphtheria	Accept immediately if feeling well and healthy
DT: Diphtheria \ Tetanus	Accept immediately if feeling well and healthy
DPT: Diphtheria \ Pertussis \ Tetanus	Accept immediately if feeling well and healthy
Flu (injection or nasal)	Accept immediately if feeling well and healthy
Gamma Globulin - prophylactic	Accept immediately if feeling well and healthy and given for general prophylaxis (e.g., for travel) and not for exposure
Gamma Globulin - exposure	<ul style="list-style-type: none"> • 120 days (4 months) if given as a precaution to Hepatitis A exposure (i.e., restaurant outbreak). • Evaluate if given for exposure to any other disease.
Hepatitis A - prophylactic	Accept immediately if feeling well and healthy
Hepatitis A – exposure	120 days (4 months)
Hepatitis B - prophylactic	2 weeks

IMMUNIZATIONS, VACCINATIONS, AND OTHER MISCELLANEOUS TREATMENTS	DEFER FOR:
Hepatitis B – exposure	12 months
Hep A + Hep B - prophylactic	2 weeks
Hep A + Hep B - exposure	12 months
HIB: Haemophilus Influenzae B	Accept immediately if feeling well and healthy
Human Papilloma Virus	Accept immediately if feeling well and healthy
IVIG (Intravenous Immune Globulin)	Defer for 12 months
Japanese Encephalitis	Accept immediately if feeling well and healthy
Lyme	Accept immediately if feeling well and healthy
Measles (Rubeola)	2 weeks
Measles, German (Rubella)	4 weeks
Meningococcus (including Meningitis B)	Accept immediately if feeling well and healthy
MMR (Measles, Mumps, Rubella)	4 weeks
Monkeypox	<ul style="list-style-type: none"> • Accept immediately if feeling well and healthy after receiving a non-replicating vaccine, such as Jynneos. If given as post-exposure prophylaxis, defer for 21 days due to exposure • 8 weeks after receiving a replication-competent vaccine used under an investigational study (IND) and is not FDA licensed, such as ACAM2000 • If complications, see “<i>Smallpox with complications</i>”
Mumps	2 weeks
Paratyphoid	Accept immediately if feeling well and healthy
Pertussis	Accept immediately if feeling well and healthy
Plague	Accept immediately if feeling well and healthy
Pneumonia	Accept immediately if feeling well and healthy
Polio: Oral	2 weeks
Polio: Injection	Accept immediately if feeling well and healthy
Rabies	<ul style="list-style-type: none"> • Accept immediately if received for prophylaxis (e.g., animal care worker) and not for exposure • Defer 12 months if due to animal bite
Rocky Mountain Spotted Fever	Accept immediately if feeling well and healthy
Shingles: Zostavax	4 weeks
Shingles: Shingrix (Zoster Vaccine Recombinant)	Accept immediately if feeling well and healthy
Smallpox without complications	8 weeks

IMMUNIZATIONS, VACCINATIONS, AND OTHER MISCELLANEOUS TREATMENTS	DEFER FOR:
Smallpox with complications	<ul style="list-style-type: none"> • 8 weeks after onset of symptoms or 14 days after symptoms resolve, whichever is longer • Complications include the following: Rash (resembling 'blisters') covering a small or large area of the body; necrosis (tissue death) in the area of vaccination; inflammation of the brain (encephalitis); infection of the cornea (eye); localized or systemic skin reaction in someone with eczema or other chronic skin condition
Tetanus Toxoid (Booster)	Accept immediately if feeling well and healthy
Tetanus and Diphtheria Toxoids	Accept immediately if feeling well and healthy
Typhoid: Injection	Accept immediately if feeling well and healthy
Typhoid: Oral	2 weeks
Typhus, Paratyphoid	Accept immediately if feeling well and healthy
Yellow Fever	2 weeks

Historical Record

Revision Date	Revision	Description of Changes	Author
08/2022	08	<ol style="list-style-type: none"> Updated COVID-19: Novavax from “2 week deferral” to “Accept immediately if feeling well and healthy” Added guidance for Monkeypox vaccines: Jynneos & ACAM2000 	M. Suehle
02/2022	07	<ol style="list-style-type: none"> Covid-19 - Removed CCP donation requirements 	M. Suehle
05/2021	06	<ul style="list-style-type: none"> Updated column header from “IMMUNIZATION OR VACCINATION” to “IMMUNIZATIONS, VACCINATIONS AND OTHER MISCELLANEOUS TREATMENTS” Removed AstraZeneca from attenuated COVID-19 vaccine example Added Johnson & Johnson as an example of a COVID-19 viral vector vaccine Added examples of COVID-19 mRNA vaccines: Pfizer/BioNTech and Comirnaty Added AstraZeneca (Covishield)/Oxford, CureVac, Novavax, and Sanofi/GSK as examples of unapproved COVID-19 vaccines in clinical trials in USA, Europe, Canada, or Australia: two week deferral period applied Added 2 week deferral period if the donor does not remember the name of the vaccine and received it in USA, Europe, Canada, or Australia Added Cansino, Bharat, Gamaleya, Sinopharm (Beijing), Sinopharm (Wuhan), Sinovac Biotech, Sputnik V and Vector Institute as examples of COVID-19 vaccines in use or in clinical trials in countries other than USA, Europe, Canada, or Australia: one year deferral period applied Added 1 year deferral period if the donor does not remember the name of the vaccine and received it in a country other than USA, Europe, Canada, or Australia Added reference to NY-JA-0521 “COVID-19 Vaccine List with Deferral Intervals” under COVID-19 vaccinations 	M. Suehle
02/2021	05	<ul style="list-style-type: none"> Modified guidance for COVID-19 monoclonal antibody therapy Updated to include current COVID-19 vaccination/antibody treatment directive Changed JA title from “Immunizations and Vaccinations” to “Immunizations, Vaccinations and other Miscellaneous Treatments” 	M. Suehle
12/2020	04	<ul style="list-style-type: none"> Deferral added for COVID-19 vaccination 	M. Suehle
06/2019	03	<ul style="list-style-type: none"> Criteria for Botulinum Toxin revised; ‘Botox’ added IVIG revised 	M. Hostetter
08/2018	02	<ul style="list-style-type: none"> See NY-SOP-0480 (SOP 301.0001) for the history of Immunizations and Vaccinations (Attachment 5) Reformatted to reflect Master Control process Allergy Desensitization one day deferral changed to accept immediately 	M. Hostetter

Revision Date	Revision	Description of Changes	Author
		<ul style="list-style-type: none">• 'Gamma Globulin – prophylactic' reworded; 'if well and healthy' replaced with 'if given for general prophylaxis (e.g., travel and not for exposure.• 'Gamma Globulin – exposure' reference to accept immediately removed	